57 related articles for article (PubMed ID: 16879623)
1. Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model.
Murray HW; Hariprashad J; Coffman RL
J Exp Med; 1997 Mar; 185(5):867-74. PubMed ID: 9120392
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-7 potentiates MAPK10-elicited host-protective vaccine against Leishmania donovani.
Kumar S; Bodhale N; Patra SK; Sarode A; Zhao L; Sarkar A; Saha B
Cytokine; 2024 Feb; 174():156475. PubMed ID: 38134556
[TBL] [Abstract][Full Text] [Related]
3. IFN-γ-induced macrophage antileishmanial mechanisms in mice: A role for immunity-related GTPases, Irgm1 and Irgm3, in Leishmania donovani infection in the liver.
Murray HW; Mitchell-Flack M; Taylor GA; Ma X
Exp Parasitol; 2015 Oct; 157():103-9. PubMed ID: 26208780
[TBL] [Abstract][Full Text] [Related]
4. Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis.
Freitas EO; Nico D; Alves-Silva MV; Morrot A; Clinch K; Evans GB; Tyler PC; Schramm VL; Palatnik-de-Sousa CB
PLoS Negl Trop Dis; 2015 Dec; 9(12):e0004297. PubMed ID: 26701750
[TBL] [Abstract][Full Text] [Related]
5. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis.
Murray HW; Delph-Etienne S
Infect Immun; 2000 Jan; 68(1):288-93. PubMed ID: 10603400
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals.
Nieto J; Alvar J; Mullen AB; Carter KC; Rodríguez C; San Andrés MI; San Andrés MD; Baillie AJ; González F
Antimicrob Agents Chemother; 2003 Sep; 47(9):2781-7. PubMed ID: 12936974
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 6 and interferon gamma haplotypes are related to cytokine serum levels in dogs in an endemic Leishmania infantum region.
Álvarez L; Marín-García PJ; Rentero-Garrido P; Martinez-Jimenez CP; Llobat L
Infect Dis Poverty; 2023 Feb; 12(1):9. PubMed ID: 36759910
[TBL] [Abstract][Full Text] [Related]
8. Detection of Leptomonas seymouri narna-like virus in serum samples of visceral leishmaniasis patients and its possible role in disease pathogenesis.
Sukla S; Nath H; Kamran M; Ejazi SA; Ali N; Das P; Ravichandiran V; Roy S; Biswas S
Sci Rep; 2022 Aug; 12(1):14436. PubMed ID: 36002553
[TBL] [Abstract][Full Text] [Related]
9. Cytokines and Signaling Networks Regulating Disease Outcomes in Leishmaniasis.
Saha A; Roy S; Ukil A
Infect Immun; 2022 Aug; 90(8):e0024822. PubMed ID: 35862725
[TBL] [Abstract][Full Text] [Related]
10.
Hartley MA; Eren RO; Rossi M; Prevel F; Castiglioni P; Isorce N; Desponds C; Lye LF; Beverley SM; Drexler SK; Fasel N
Microb Cell; 2018 Jan; 5(3):137-149. PubMed ID: 29487860
[TBL] [Abstract][Full Text] [Related]
11. Inducible nitric oxide synthase response and associated cytokine gene expression in the spleen of mice infected with Clonorchis sinensis.
Shen JQ; Yang QL; Xue Y; Cheng XB; Jiang ZH; Yang YC; Chen YD; Zhou XN
Parasitol Res; 2015 May; 114(5):1661-70. PubMed ID: 25687522
[TBL] [Abstract][Full Text] [Related]
12. Association of interleukin-18 gene variants with susceptibility to visceral leishmaniasis in Iranian population.
Moravej A; Rasouli M; Asaei S; Kalani M; Mansoori Y
Mol Biol Rep; 2013 Jun; 40(6):4009-14. PubMed ID: 23269628
[TBL] [Abstract][Full Text] [Related]
13. Classification and regression tree and spatial analyses reveal geographic heterogeneity in genome wide linkage study of Indian visceral leishmaniasis.
Fakiola M; Mishra A; Rai M; Singh SP; O'Leary RA; Ball S; Francis RW; Firth MJ; Radford BT; Miller EN; Sundar S; Blackwell JM
PLoS One; 2010 Dec; 5(12):e15807. PubMed ID: 21209823
[TBL] [Abstract][Full Text] [Related]
14. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.
Mullen AB; Lawrence CE; McFarlane E; Wei XQ; Carter KC
Immunology; 2006 Nov; 119(3):348-54. PubMed ID: 16879623
[TBL] [Abstract][Full Text] [Related]
15. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis.
Alexander J; Carter KC; Al-Fasi N; Satoskar A; Brombacher F
Eur J Immunol; 2000 Oct; 30(10):2935-43. PubMed ID: 11069076
[TBL] [Abstract][Full Text] [Related]
16. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
Bimal S; Sinha S; Singh SK; Narayan S; Kumar V; Verma N; Ranjan A; Sinha PK; Das VN; Pandey K; Kar SK; Das P
Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
[TBL] [Abstract][Full Text] [Related]
17. Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations.
Banduwardene R; Mullen AB; Carter KC
Int J Immunopharmacol; 1997 Apr; 19(4):195-203. PubMed ID: 9373770
[TBL] [Abstract][Full Text] [Related]
18. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.
Lehmann J; Enssle KH; Lehmann I; Emmendörfer A; Lohmann-Matthes ML
J Interferon Cytokine Res; 2000 Jan; 20(1):63-77. PubMed ID: 10670653
[TBL] [Abstract][Full Text] [Related]
19. Interferon-gamma and interleukin-4 in human Leishmania donovani infections.
Kemp M; Kurtzhals JA; Kharazmi A; Theander TG
Immunol Cell Biol; 1993 Dec; 71 ( Pt 6)():583-7. PubMed ID: 8314285
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
